Award Data

Juvenile myelomonocytic leukemia (JMML) is a rare hematologic malignancy of early childhood with high mortality. JMML accounts for 1-2% of childhood leukemias each year; in the United States, an estimated 25-50 new cases are diagnosed each year. JMML predominately affects young children, most often developing in children under the age of 4. Currently, the only effective treatment for most JMML pat ...

Supervised, Machine Learning based oncologic AI algorithms degrade over time and don’t generalize well. The FDA requires the conduct of standalone testing of radiologic, AI products to characterize their performance. Sourcing representative data with sufficient variability is time consuming, expensive, and often under-represent the variety of image quality experienced in clinical reality. FDA Re ...

With brain metastases (BMs) incidences rapidly increasing due to improved systemic treatment and cancer patients, survival, the BMs management strategies have evolved substantially from whole brain irradiation to localized multisession SRS. The evolution requires contouring and distributed SRS planning for multiple BMs and treatment followups and has put a high demand on care teams time, efforts, ...

The availability of low-cost video has tremendous potential to provide new insight into how physical behavior is associated with health, define clinical trial outcomes, and assess physical function within the home, research and clinical environments. The COVID-19 pandemic required a rapid shift to incorporate video-based data collection and clinical visits, establishing the feasibility of using vi ...

Autologous cell-based therapies offer great promise for cancer treatment however they are complex, slow, labor intensive and expensive. Medical center laboratories usually have a limited capacity and they can rarely treat more than 10 patients per month. Advanced manufacturing approaches that can process multiple cell therapies for several patients in parallel are desperately needed to improve the ...

In Phase I, we were able to prototype several features for Atlascope and demonstrate that they form a plausible system in which to conduct multiscale biological workflows and visualizations. In Phase II, we will aim to scale up our Phase I success in several directions: technologically, we will aim to harden the features and the web application we have developed to host our Phase I experiments; bi ...

Mass spectrometry-based proteomics can now quantify up to thousands of proteins from trace samples including single cells, yet such studies require highly specialized, custom-built consumables and instrumentation, and are thus out of reach of most laboratories. Commercial solutions now exist for cell isolation and reagent dispensing at the beginning of the single-cell proteomics (SCP) workflow, an ...

Integrative analysis of multi-omics datasets is revolutionizing cancer research and patient care. To take advantage of the full breadth of CRDC’s petabyte-scale data, EarlyDx will seamlessly integrate its liquid biopsy cloud-computing platform with CRDC data repositories. Liquid biopsies provide a non-invasive approach for interrogating the genomic and epigenomic profiles of tumors. Co-analysis ...

Artificial intelligence (AI)-based software devices are starting to play key roles in healthcare with more and more regulatory approval and clinical adoptions. Segmentation is a key task in oncology settings including radiation treatment planning and volumetric assessment to assist cancer diagnosis and treatment monitoring. In radiation oncology, multiple AI segmentation devices have obtained FDA ...

The goal of this proposal is to create a medical device development tool (MDDT) for use during performance evaluation of artificial intelligence (AI)-based radiotherapy software. The MDDT is intended to be used by manufacturers during external validation, whereby AI models are tested for generalizability. Test results can be used for pre-market submissions to the Food and Drug Administation (FDA) ...